Stable SNS-595 compositions and methods of preparation
View Patent ↗Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
1. A composition comprising substantially pure SNS-595 substance, wherein the substantially pure SNS-595 substance comprises 0 to 0.02% Compound 4
and 0 to 0.1% Compound 7
based on total weight of the substantially pure SNS-595 substance.
2. The composition of claim 1 , wherein the substantially pure SNS-595 further comprises 0 to 0.02% Compound 5
based on total weight of the substantially pure SNS-595 substance.
3. The composition of claim 1 comprising 0 to 0.01% Compound 4 based on total weight of the substantially pure SNS-595 substance.
4. The composition of claim 2 consisting essentially of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid, 0 to 0.02% Compound 4, 0 to 0.1% Compound 7 and 0 to 0.02% Compound 5 based on total weight of the composition.
5. The composition of claim 1 , wherein the composition further comprises water.
6. The composition of claim 5 , wherein the composition has pH 2.5.
7. A pharmaceutical composition comprising the composition of claim 1 and one or more pharmaceutically acceptable ingredients.
8. An aqueous solution comprising the composition of claim 1 and water, wherein about 100 mg of substantially pure SNS-595 substance is present for every 10 mL of the aqueous solution, the aqueous solution is essentially free of visible particles, and the aqueous solution maintains not more than 1000 particles ≧10 microns per 10 mL of the aqueous solution when stored for at least 1 month.
9. The aqueous solution of claim 8 , wherein the aqueous solution consists essentially of 100 mg substantially pure SNS-595 substance, 450 mg sorbitol, water, and methanesulfonic acid, wherein the pH of the aqueous solution is about 2.5, and wherein water is present in an amount to provide a total solution volume of 10 mL.
10. The aqueous solution of claim 9 , wherein the aqueous solution maintains not more than 1000 particles ≧10 microns per 10 mL of the aqueous solution when stored for at least 6 months.
11. A composition consisting essentially of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid, 0 to 0.02 wt % Compound 4
and 0 to 0,1 wt % Compound 7
based on total weight of the composition.
12. The composition of claim 11 , wherein the (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid is in form of a hydrate.
13. A composition consisting essentially of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid, and comprising 0 to 0.02 wt % Compound 4
0 to 0,02 wt % Compound 5
and 0 to 0.1 wt % Compound 7
based on total weight of the composition.
14. A composition comprising water and a substantially pure SNS-595 substance that consists essentially of(+)-1,4-dihydro-7-[3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazoly)-1,8-naphthyridine-3-carboxylic acid, and comprising 0 to 0.02 wt % Compound 4
0 to 0.02 wt % Compound 5
and 0 to 0.1 wt % Compound 7
based on the weight of the substantially pure SNS-595 substance.